Claritev (CTEV) stock price is $21.99, down 0.59% on the day, as of Oct 19, 2026. It has a market cap of $370.68Mn, and is classified in the Healthcare IT industry (Technology sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap370.68 Mn
P/E-1.31
P/S0.37
Div. Yield0.00
Total Debt (Qtr)4.60 Bn
Revenue Growth (1y) (Qtr)6.59
Add ratio to table…
About
Claritev Corporation is a technology data and insights company focused on improving transparency affordability and quality across the healthcare system. The company applies data analytics and artificial intelligence to help payers employers and providers understand costs pricing and payment dynamics. Founded in 1980 Claritev draws on over 45 years of claims experience to deliver solutions that reduce medical cost burdens and support fair reimbursements. The company’s…
Claritev Corporation is a technology data and insights company focused on improving transparency affordability and quality across the healthcare system. The company applies data analytics and artificial intelligence to help payers employers and providers understand costs pricing and payment dynamics. Founded in 1980 Claritev draws on over 45 years of claims experience to deliver solutions that reduce medical cost burdens and support fair reimbursements. The company’s mission is to bring transparency affordability and quality to the healthcare system by turning claims data into actionable insights. Claritev leverages artificial intelligence and machine learning to analyze vast datasets and identify cost saving opportunities for its clients.
Claritev generates revenue by selling its four solution categories to healthcare payers third party administrators employers brokers consultants providers and government entities. The company offers claims intelligence network payment and revenue integrity and data and analytics solutions that are typically delivered under multi year contracts with automatic renewal provisions. The majority of revenue comes from fees charged per claim processed or per member per month depending on the solution. Long term contracts with automatic renewals provide a stable revenue base and support ongoing investment in technology and data assets. Revenue is primarily recurring reflecting the ongoing use of its platform to process claims and provide analytics services.
The company operates through the following segments: Claims Intelligence Solutions Network Solutions Payment and Revenue Integrity Solutions and Data and Analytics Solutions. These segments reflect the way management evaluates performance and allocates resources.
Claims Intelligence Solutions: This segment provides data driven algorithms and insights that identify out of network claims priced above fair market value and negotiates or recommends appropriate reimbursement using reference based pricing and negotiation services including Vistara solutions that bundle reference based pricing with member and provider engagement tools.
Network Solutions: This segment delivers contracted discounts with more than 1,400,000 healthcare providers forming one of the preferred provider organizations in the United States and offers outsourced network development and management services that are applied before claim payment.
Payment and Revenue Integrity Solutions: This segment uses data technology and clinical expertise to detect improper unnecessary and excessive charges before or after claims are paid and to recover underpaid premium dollars through services such as clinical negotiation pre payment integrity post payment integrity coordination of benefits subrogation and revenue integrity for Medicare Advantage plans.
Data and Analytics Solutions: This segment provides descriptive predictive and prescriptive analytics to help customers optimize benefit plan design improve clinical outcomes and reduce total cost of care through products such as PlanOptix CompleteVue BenInsights Risk Scores Supplemental Carrier Services and Medical Claims Integration.
Claritev holds a leading position as an independent provider of cost management and payment integrity solutions in the United States healthcare market. The company differentiates itself through long standing relationships with over 750 payers a deeply integrated technology platform that processes claims before payment and proprietary data assets accumulated from decades of claims experience. Competitors vary by service and include firms such as 6Degrees Zelis Optum Conduent Cotiviti and Milliman among others. Claritev’s advantages also stem from its operational scale processing billions of dollars in claim charges annually and its ability to bundle multiple solutions into a single workflow for clients. The company’s proprietary claim pricing methodologies are supported by a patented benchmarking process that enhances provider acceptance and ensures fair reimbursements. Claritev’s nationwide network of over 1,400,000 contracted providers gives it a scale advantage that few competitors can match.
Claritev serves a diverse customer base that includes commercial healthcare payers third party administrators employers brokers consultants providers government healthcare payers and system integrators. The company works with over 750 payers and more than 100,000 employers and plan sponsors whose members collectively represent over 60,000,000 individuals with access to its solutions. Although Claritev’s direct clients are primarily payers and third party administrators the ultimate beneficiaries of its solutions are employers plan sponsors and the patients and members they serve. The company’s solutions are available in all fifty states and the District of Columbia allowing broad geographic reach. While specific customer names are not disclosed the filing notes that a small number of large accounts contribute a significant portion of total revenue.
Sector:TechnologySector rationaleClaritev's primary revenue is derived from selling a technology platform that uses AI, machine learning, and data analytics to process claims and provide insights (e.g., PlanOptix, CompleteVue). While it operates exclusively within the healthcare domain, its core product is software and data infrastructure sold as a service to payers and employers, which aligns with the Technology sector's 'Healthcare IT' and 'Analytics and BI' industries. A secondary sector of Healthcare is justified because the company provides clinical expertise and specialized payment integrity services (e.g., clinical negotiation and revenue integrity) that go beyond software to deliver healthcare-specific operational services.Industries:Healthcare ITHealthcare ITPrimaryClaritev provides a technology platform purpose-built for healthcare administration, specifically focusing on claims intelligence, payment integrity, and revenue cycle management for payers and providers. Its products, such as PlanOptix and CompleteVue, are designed around healthcare-specific workflows like medical claims processing and reimbursement dynamics.Analytics and BIAnalytics and BISecondaryThe company has a dedicated 'Data and Analytics Solutions' segment that provides descriptive, predictive, and prescriptive analytics to help customers optimize benefit plan design and reduce the total cost of care.Classified using BQ-MICSCIK: 0001793229
Bull & bear
Investment Thesis
▲ Bull case
Claritev is positioned to capitalize on a structural shift toward AI-driven operational efficiency that management underemphasized during the Q&A, where they revealed internal engineering teams are nearly doubling coding capacity without headcount growth through widespread AI tool adoption—a metric not reflected in reported financials but signaling substantial margin expansion potential as these productivity gains scale across sales, finance, and client-facing workflows beyond the highlighted claims intelligence examples. This hidden catalyst addresses investor skepticism about AI ROI in regulated industries by demonstrating tangible internal efficiency improvements that directly support their long-term deleveraging goals while maintaining adjusted EBITDA margins in the 60%+ range, creating a pathway to exceed the $1 billion revenue target through self-funded innovation rather than dilutive investment.
The company's expansion into the TPA market via PHCS Novera represents an underappreciated growth vector that aligns with unspoken pressures from employers demanding cost-control solutions amid projected 9.5% healthcare cost inflation in 2026—a trend management noted but did not quantify in terms of addressable market size or timing of revenue contribution, despite Dallas Scrip's hire signaling serious commitment to this vertical; with TPAs managing nearly two-thirds of self-funded plans, Claritev's ability to bundle regional network depth with national access through solutions like PHCS Novera taps into a durable structural shift away from monolithic payer networks, creating recurring revenue opportunities that complement their core PSAV business where growth is already shifting toward higher-acuity, complex claims less vulnerable to utilization fluctuations.
Claritev's strategic focus on converting ACV to revenue exhibits de-risked execution visibility that the market overlooks, as evidenced by Q1 bookings showing 73% from cross-sell/upsell to existing clients—a mix indicating lower customer acquisition cost and faster revenue recognition compared to pure new logo hunting—while management disclosed a pipeline coverage ratio of 4.8x quota (up from 1.5x two years prior) without elaborating on how this dramatically improves forecast accuracy for the $80-$100M ACV target, reducing the perceived risk of execution delays in their growth initiatives and supporting confidence in achieving the 3-5% second-half revenue acceleration guided for FY26.
Claritev is positioned to capitalize on a structural shift toward AI-driven operational efficiency that management underemphasized during the Q&A, where they revealed internal engineering teams are nearly doubling coding capacity without headcount growth through widespread AI tool adoption—a metric not reflected in reported financials but signaling substantial margin expansion potential as these productivity gains scale across sales, finance, and client-facing workflows beyond the highlighted claims intelligence examples. This hidden catalyst addresses investor skepticism about AI ROI in regulated industries by demonstrating tangible internal efficiency improvements that directly support their long-term deleveraging goals while maintaining adjusted EBITDA margins in the 60%+ range, creating a pathway to exceed the $1 billion revenue target through self-funded innovation rather than dilutive investment.
The company's expansion into the TPA market via PHCS Novera represents an underappreciated growth vector that aligns with unspoken pressures from employers demanding cost-control solutions amid projected 9.5% healthcare cost inflation in 2026—a trend management noted but did not quantify in terms of addressable market size or timing of revenue contribution, despite Dallas Scrip's hire signaling serious commitment to this vertical; with TPAs managing nearly two-thirds of self-funded plans, Claritev's ability to bundle regional network depth with national access through solutions like PHCS Novera taps into a durable structural shift away from monolithic payer networks, creating recurring revenue opportunities that complement their core PSAV business where growth is already shifting toward higher-acuity, complex claims less vulnerable to utilization fluctuations.
Claritev's strategic focus on converting ACV to revenue exhibits de-risked execution visibility that the market overlooks, as evidenced by Q1 bookings showing 73% from cross-sell/upsell to existing clients—a mix indicating lower customer acquisition cost and faster revenue recognition compared to pure new logo hunting—while management disclosed a pipeline coverage ratio of 4.8x quota (up from 1.5x two years prior) without elaborating on how this dramatically improves forecast accuracy for the $80-$100M ACV target, reducing the perceived risk of execution delays in their growth initiatives and supporting confidence in achieving the 3-5% second-half revenue acceleration guided for FY26.
Claritev faces significant headwinds from its unsustainable capital structure that management consistently avoids addressing directly, as highlighted by the Q1 cash flow statement showing $129.3 million in interest paid versus only $36.8 million of unlevered free cash flow—a coverage ratio of just 0.28x that necessitates aggressive revolver borrowing ($145 million drawn in Q1) to service debt, with long-term debt at $4.57 trillion creating a refinancing cliff risk that contradicts their Vision 2030 narrative and forces allocation of cash flow to interest rather than growth investments or deleveraging, a structural vulnerability exposed when Doug Garis acknowledged Q1 and Q3 are expected cash consumption quarters due to the debt schedule.
The company's reliance on PSAV revenue presents a hidden vulnerability masked by favorable rate mix trends, as management admitted to modest volume declines in Q1 that were offset by higher-acuity claims—a dynamic that may not persist if employer cost-containment pressures intensify under Medicare Advantage rate scrutiny, which Travis Dalton dismissed as having "limited impact" on volumes despite Stan Berenshteyn's question about payment integrity demand growth, revealing a potential disconnect between management's optimism and actual payer behavior shifts toward reducing utilization that could undermine the core business where 80% of identified savings historically derive from outpatient higher-acuity areas.
Claritev's services expansion strategy carries unacknowledged execution risks that management glossed over when discussing the OPCG acquisition and top 5 health system win, as Doug Garis conceded service line margins are expected to be "roughly half the core business" while revealing only 20% of Q1 bookings came from provider/public sector verticals—indicating these strategic initiatives are currently contributing minimally to overall profitability despite requiring significant incremental investment ($20-$25M annualized), with Jessica Tassan's question about service margin progression left unanswered beyond vague assurances of recurrence, suggesting the market may be overestimating the near-term profitability and scalability of these newer offerings relative to the core network and payment integrity businesses.
Claritev faces significant headwinds from its unsustainable capital structure that management consistently avoids addressing directly, as highlighted by the Q1 cash flow statement showing $129.3 million in interest paid versus only $36.8 million of unlevered free cash flow—a coverage ratio of just 0.28x that necessitates aggressive revolver borrowing ($145 million drawn in Q1) to service debt, with long-term debt at $4.57 trillion creating a refinancing cliff risk that contradicts their Vision 2030 narrative and forces allocation of cash flow to interest rather than growth investments or deleveraging, a structural vulnerability exposed when Doug Garis acknowledged Q1 and Q3 are expected cash consumption quarters due to the debt schedule.
The company's reliance on PSAV revenue presents a hidden vulnerability masked by favorable rate mix trends, as management admitted to modest volume declines in Q1 that were offset by higher-acuity claims—a dynamic that may not persist if employer cost-containment pressures intensify under Medicare Advantage rate scrutiny, which Travis Dalton dismissed as having "limited impact" on volumes despite Stan Berenshteyn's question about payment integrity demand growth, revealing a potential disconnect between management's optimism and actual payer behavior shifts toward reducing utilization that could undermine the core business where 80% of identified savings historically derive from outpatient higher-acuity areas.
Claritev's services expansion strategy carries unacknowledged execution risks that management glossed over when discussing the OPCG acquisition and top 5 health system win, as Doug Garis conceded service line margins are expected to be "roughly half the core business" while revealing only 20% of Q1 bookings came from provider/public sector verticals—indicating these strategic initiatives are currently contributing minimally to overall profitability despite requiring significant incremental investment ($20-$25M annualized), with Jessica Tassan's question about service margin progression left unanswered beyond vague assurances of recurrence, suggesting the market may be overestimating the near-term profitability and scalability of these newer offerings relative to the core network and payment integrity businesses.